• Adaptimmune Therapeutics PLC ADAP.OQ reported a quarterly adjusted loss of 2 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 24 cents. The mean expectation of six analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -13 cents to -3 cents per share.

• Revenue fell 89.3% to $13.68 million from a year ago; analysts expected $10.03 million.

• Adaptimmune Therapeutics PLC's reported EPS for the quarter was a loss of 2 cents​.

• The company reported a quarterly loss of $30.34 million.

• Adaptimmune Therapeutics PLC shares had fallen by 68.0% this quarter and lost 85.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 21.6% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Adaptimmune Therapeutics PLC is $0.46, about 83.3% above its last closing price of $0.08

This summary was machine generated from LSEG data August 13 at 12:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)